Company news
Inhibrx Biosciences, Inc. (NASDAQ:INBX) news
Inhibrx Biosciences, Inc. news releases on 6ix. Latest, Sep 8, 2026: Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6…
Press releases & updates
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
September 8, 2026
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
September 4, 2026
Inhibrx Reports Second Quarter 2026 Financial Results
August 13, 2026
Inhibrx Biosciences : Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
July 16, 2026
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
June 15, 2026
Inhibrx Reports First Quarter 2026 Financial Results
May 14, 2026
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
May 11, 2026
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
May 8, 2026
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
April 21, 2026
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
April 20, 2026
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
March 19, 2026
Inhibrx Announces Participation in Upcoming Scientific Conference
March 2, 2026
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
December 16, 2025
Inhibrx Reports Third Quarter 2025 Financial Results
November 14, 2025
Inhibrx Announces Participation in Upcoming Scientific Conferences
November 4, 2025
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
October 23, 2025
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
October 22, 2025
Inhibrx Reports Second Quarter 2025 Financial Results
August 13, 2025
Inhibrx Reports First Quarter 2025 Financial Results
May 14, 2025
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
April 1, 2025
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
March 17, 2025
Inhibrx Biosciences : Reports Third Quarter 2024 Financial Results Form 8 K
November 14, 2024
Inhibrx Biosciences : Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights Form 8 K
August 13, 2024